MYOMO INC. NEW DL-,0001

Myomo reported Q2 revenue of $11.7 million, up 21% year over year, driven by a 19% increase in recognized MyoPro units to 211 and a record 255 orders. Recurring referral sources now account for 53% of quarterly revenue (vs. 26% a year earlier) as the company expands its referral network above 300 sites. Gross margin improved to 72.1% and operating loss narrowed to $2.3 million; adjusted EBITDA loss fell to $800,000. Management raised full-year 2026 revenue guidance to $45 million–$47 million, expects Q3 revenue of $11.5 million–$12 million, and forecasts second-half cash burn below $2 million. » Altro su finance.yahoo.com

Myomo reported a 21% rise in Q2 revenue to $11.7 million, a reduced net loss of $0.09 per share and a markedly improved gross margin of 72.1%. The quarter was supported by a record order intake of 255 MyoPro units and 211 devices delivered. The company raised its 2026 revenue guidance to $45–47 million and signaled progress on operating leverage. The stock rose modestly in after-hours trading following the results. » Altro su de.investing.com

Myomo reported better-than-expected Q1 results: EPS -$0.07 (expected -$0.12) and revenue $10.1 million (expected $9.24 million). Revenue rose 3% year-on-year, gross margin improved to 68.2%, and the company shipped 172 MyoPro units. For Q2 Myomo forecasts revenue between $10.3 million and $10.8 million; nevertheless the stock fell after-hours, initially by 2.98% and then declined further. » Altro su de.investing.com

Myomo has appointed Joseph M. Manko Jr. to the board of directors effective Friday; his mandate runs until the annual general meeting in 2027, bringing the board to seven members. Manko is Senior Principal at Horton Capital Management, founder of the Horton Fund and brings more than 25 years of experience in investment banking, private equity and corporate strategy. The company reports a current ratio of 2.73 and its stock trades at $0.82 after a one-year loss of 76%. Myomo manufactures the motorized upper-arm orthosis MyoPro for patients with neurological disorders and paralysis of the upper limbs. » Altro su de.investing.com

Myomo will make its motorized arm orthosis MyoPro available nationwide at Ottobock Care’s more than 50 clinics in the US. Ottobock Care has trained staff and has already treated several patients, giving Myomo access to a larger, previously partly underserved patient market. Myomo emphasizes that Medicare and, increasingly, insurers cover costs on a case-by-case basis, which improves market prospects. The company most recently recorded USD 40.93 million in revenue and, according to analysis, has a low market capitalization relative to fair value. » Altro su de.investing.com